Status: Recruiting
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
To learn if revumenib (also known as SNDX-5613) can help to control leukemias associated with an increase in expression of HOX genes.
Participants needed: 40
Trial details
Phase: Phase 2Age: 12+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Sep 11, 2026Locations: 2
Eligibility criteria
Age ≥ 12 years with weight ≥ 40Kg. [+8]
Participants with any concurrent uncontrolled medical condition, laboratory abno... [+12]